Century Therapeutics Inc (IPSC)
$3.12
+0.16
(+5.41%)▲
Live
Insights on Century Therapeutics Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 99.0K → 268.0K (in $), with an average increase of 38.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -32.72M → -39.39M (in $), with an average decrease of 20.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 53.9%
Performance
- $2.86$3.17$3.12
8.33%
Downside
Day's Volatility :9.77%
Upside
1.56%
- $1.28$5.51$3.12
58.97%
Downside
52 Weeks Volatility :76.77%
Upside
43.38%
Returns
| Period | Century Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -31.64% | 1.7% | 0.0% |
6 Months | 100.0% | 11.3% | 0.0% |
1 Year | -4.21% | 5.4% | 1.3% |
3 Years | -89.28% | 13.9% | -22.1% |
Highlights
Market Capitalization | 202.9M |
Book Value | $3.06 |
Earnings Per Share (EPS) | -2.3 |
Wall Street Target Price | 14.83 |
Profit Margin | 0.0% |
Operating Margin TTM | -11424.25% |
Return On Assets TTM | -18.47% |
Return On Equity TTM | -56.07% |
Revenue TTM | 2.2M |
Revenue Per Share TTM | 0.04 |
Quarterly Revenue Growth YOY | -48.6% |
Gross Profit TTM | 5.2M |
EBITDA | -112.1M |
Diluted Eps TTM | -2.3 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.04 |
EPS Estimate Next Year | -1.88 |
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Next Quarter | -0.59 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 375.32%
Technicals Summary
Sell
Neutral
Buy
Century Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Century Therapeutics Inc | -26.18% | 100.0% | -4.21% | -89.28% | -89.28% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Century Therapeutics Inc | 45.5 | NA | NA | -2.04 | -0.56 | -0.18 | NA | 3.06 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Century Therapeutics Inc | Buy | $202.9M | -89.28% | 45.5 | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
FMR Inc
5.57%Casdin Capital, LLC
4.95%BlackRock Inc
2.34%Avidity Partners Management LP
2.09%Dafna Capital Management LLC
2.02%Vanguard Group Inc
1.74%
Company Information
Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.
Organization | Century Therapeutics Inc |
Employees | 152 |
CEO | Dr. Adrienne Farid Ph.D. |
Industry | Non-Energy Minerals |
